Hong Kong is recruiting for its Centre for Medical Products Regulation, expected to launch by the fourth quarter of 2026, as it seeks World Health Organization recognition and aims for independent drug approvals by 2030.
Hong Kong is conducting a global talent search to staff its future Centre for Medical Products Regulation. The body is scheduled to begin operations by the fourth quarter of this year.
Secretary for Health Lo Chung-mau said the government is in discussions with mainland Chinese authorities to obtain World Health Organization recognition for the centre. This step is viewed as essential for establishing the regulator as an internationally accepted primary evaluator of drugs.
In the past Hong Kong approved drug registrations only after two other economies or jurisdictions had confirmed quality, safety and efficacy standards. Lo noted that this approach prevented the city from being among the first to access advanced medicines.
The reforms align with national policy and the development of the Greater Bay Area. The city marks the 29th anniversary of its return to Chinese rule on July 1.